Disease progression and costs at the 3‐year follow‐up of the GERAS‐US study

INTRODUCTION: GERAS‐US prospectively characterized clinical and economic outcomes of early symptomatic Alzheimer's disease (AD). Societal cost changes were examined in amyloid‐positive patients with mild cognitive impairment due to AD (MCI) and mild dementia due to AD (MILD). METHODS: Cognition...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandler, Julie M., Rentz, Dorene M., Zagar, Anthony, Kim, Yongin, Schwartz, Ronald L., Fillit, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113935/
https://www.ncbi.nlm.nih.gov/pubmed/37091310
http://dx.doi.org/10.1002/dad2.12430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113935/
https://www.ncbi.nlm.nih.gov/pubmed/37091310
http://dx.doi.org/10.1002/dad2.12430

Ejemplares similares